Stereoselectivity of Superacid-Catalyzed Pictet−Spengler Cyclization Reactions
摘要:
High stereoselectivities were found in a wide range of superacid-catalyzed Pictet-Spengler cyclization reactions. Particularly in the cases of 2-alkyl-N-benzylidene-2-phenethylamines, an enhanced stereoselectivity was observed under the superacid conditions as compared with the corresponding weak acid (TFA)-catalyzed (monocationic) cyclization reaction of the N-benzylidene-2-(3',4'-dimethoxy)phenethylamines that bear electron-donating groups on the cyclizing aromatic ring. The computational study also supported the energetic favorability of the cyclization of the N,N-diprotonated imine and revealed a significantly early transition-state structure.
二氧化硅负载的超小 Ni 纳米颗粒允许在温和条件下将各种腈类普遍和选择性地氢化为伯胺。通过煅烧由 Ni( II ) 生成的模板材料)硝酸盐和胶体二氧化硅在空气下,随后在分子氢存在下还原,制备最佳催化剂。制备的负载型纳米颗粒稳定,使用方便,易于回收利用。最佳催化剂材料的适用性通过对超过 110 种不同的脂肪族和芳香族腈(包括功能化和工业相关底物)进行氢化来证明。具有挑战性的杂环腈,特别是氰基吡啶,以良好的收率提供了相应的伯胺。所得胺可作为制备众多生命科学产品和聚合物的重要前体和中间体。
[EN] PRODRUGS OF SECONDARY AMINE COMPOUNDS<br/>[FR] PROMÉDICAMENTS DE COMPOSÉS AMINE SECONDAIRES
申请人:ALKERMES PHARMA IRELAND LTD
公开号:WO2013088255A1
公开(公告)日:2013-06-20
The present invention relates to compounds of Formula (I).
本发明涉及式(I)的化合物。
Cobalt-based nanoparticles prepared from MOF–carbon templates as efficient hydrogenation catalysts
作者:Kathiravan Murugesan、Thirusangumurugan Senthamarai、Manzar Sohail、Ahmad S. Alshammari、Marga-Martina Pohl、Matthias Beller、Rajenahally V. Jagadeesh
DOI:10.1039/c8sc02807a
日期:——
resulting nanoparticles create stable and reusable catalysts for selective hydrogenation of functionalized and structurally diverse aromatic, heterocyclic and aliphaticnitriles, and as well as nitro compounds to primary amines (>65 examples). The synthetic and practical utility of this novel non-noble metal-based hydrogenation protocol is demonstrated by upscaling several reactions to multigram-scale
用于工业相关氢化反应的高效和选择性纳米结构催化剂的开发继续是化学研究的实际目标。尤其是腈和硝基芳烃的氢化对于伯胺的生产非常重要,伯胺构成了高级化学品,生命科学分子和材料的重要原料和关键中间体。在这里,我们报道了石墨烯壳包封的Co 3 O 4的制备-和钴-纳米颗粒通过碳上对苯二甲酸钴对苯二甲酸MOF的模板合成和随后的热解而负载在碳上。所得的纳米颗粒产生稳定且可重复使用的催化剂,用于官能化和结构多样的芳族,杂环和脂肪族腈以及硝基化合物选择性氢化为伯胺(> 65实例)。这种新型的基于非贵金属的氢化方案的合成和实用性通过将数种反应的规模扩大到数克规模并回收催化剂得到了证明。
Hydroxylated nebivolol metabolites
申请人:O'Donnell P. John
公开号:US20070014733A1
公开(公告)日:2007-01-18
Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6′difluoro-, 4-hydroxy-5-phenol-6,6′difluoro-, and 4-hydroxy-8-pheno-6,6′difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. This invention provides hydroxylated nebivolol metabolites and compositions comprising nebivolol and/or at least one hydroxylated metabolite of nebivolol and/or at least one additional compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof. In addition, this invention provides methods of treating and/or preventing vascular diseases by administering at least one hydroxylated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one hydroxylated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.
Nitric Oxide Releasing Prodrugs of Therapeutic Agents
申请人:SATYAM Apparao
公开号:US20110263526A1
公开(公告)日:2011-10-27
The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents which are represented herein as compounds of formula (I) wherein the drugs or therapeutic agents contain one or more functional groups independently selected from a carboxylic acid, an amino, a hydroxyl and a sulfhydryl group. The invention also relates to processes for the preparation of the nitric oxide releasing prodrugs (the compounds of formula (I)), to pharmaceutical compositions containing them and to methods of using the prodrugs.
3-Disubstituted N-phosphorylated aziridines except N-phosphorylated cyclohexenimine (4) do not react under the described conditions. Copper-mediated reaction of 2-phenyl-N-(diethoxyphosphoryl)aziridine (7) with Grignard reagents affords a mixture of regioisomers (8) and (9) but still with the preference of ring-opening at the carbon of lesser substitution.